EMA/562274/2013

European Medicines Agency decision

P/0226/2013

of 23 September 2013

on the acceptance of a modification of an agreed paediatric investigation plan for nonacog beta pegol, (EMEA-000731-PIP01-09-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0226/2013

of 23 September 2013

on the acceptance of a modification of an agreed paediatric investigation plan for nonacog beta pegol, (EMEA-000731-PIP01-09-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/292/2010 issued on 22 December 2010,

Having regard to the application submitted by Novo Nordisk A/S on 16 May 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 August 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for nonacog beta pegol, powder and solvent for solution for injection, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novo Nordisk A/S, Novo Allé 1, 2880 – Bagsværd, Denmark.

Done at London, 23 September 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/319148/2013

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000731-PIP01-09-M01

Scope of the application

Active substance(s):

Nonacog beta pegol

Condition(s):

Treatment of hereditary factor IX deficiency

Pharmaceutical form(s):

Powder and solvent for solution for injection

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Novo Nordisk A/S

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novo Nordisk A/S submitted to the European Medicines Agency on 16 May 2013 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/292/2010 issued on 22 December 2010.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 12 June 2013.

Scope of the modification

Some measures and timelines of the agreed Paediatric Investigation Plan have been modified.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 9 August 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: treatment of hereditary factor IX deficiency

2.1.1. Indication(s) targeted by the PIP

Treatment and prophylaxis of bleeding in haemophilia B

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for injection, intravenous use

2.1.4. Measures

Area	Number of studies	Description
Quality	1	Development of a 250 UI vial
Non-clinical	0	Not applicable.
Clinical	4	Multi-centre, open-label study to assess PK, tolerability/safety and efficacy of on-demand and prophylactic treatment with N9-GP in adults and adolescents with haemophilia B Non-randomised, open-label, multicentre, multinational, single-arm, non-controlled, efficacy and safety trial to assess the efficacy and safety of N9-GP during surgical procedures in patients with haemophilia B Open-label, multicentre, uncontrolled, PK, safety and efficacy trial to assess the effect of N9-GP in children less than 12 years of age with haemophilia B Open-label, multicentre, uncontrolled, safety and efficacy trial in previously untreated patients with haemophilia B

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By October 2020
Deferral for one or more measures contained in the paediatric investigation plan:	Yes